Numinus Wellness Receives Health Canada Special Access Program Applicant Approval to Provide Psychedelic-assisted Therapy Treatment
Approval Marks Numinus’ First use of Psilocybin-Assisted Therapy Treatment Outside of Clinical Trials VANCOUVER, BC, May 16, 2022 – Numinus Wellness Inc.(TSX: NUMI)(OTC:NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, ... [Read]
Numinus Announces the Music as Medicine Event Series
Music As Medicine by Numinus is a series of Meditative Musical Experiences & Creative Content Featuring Jon Hopkins, East Forest And Superposition VANCOUVER, BC, April 29, 2022 – Numinus Wellness Inc.(TSX: NUMI)(OTC:NUMIF) (“Numinus” or the ... [Read]
Numinus to Acquire Novamind, Creating the North American Industry Leader in Psychedelic Therapy and Research
Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory Shared mission of responsibly reintroducing psychedelic therapy to mental healthcare Hosting clinical ... [Read]
Numinus Completes First MDMA Administration in PTSD Trial Sponsored by MAPS
Update marks the first MDMA-assisted therapy session at a Numinus clinic VANCOUVER, BC, March 30, 2022 – Numinus Wellness Inc. (TSX:NUMI)(OTCPK:LKYSF) (“Numinus” or the “Company”), a mental healthcare company advancing innovative treatments and safe, evidence-based ... [Read]
Numinus Wellness Announces Voting Results From its Annual General and Special Meeting of Shareholders
VANCOUVER, BC, Feb. 28, 2022 – Numinus Wellness Inc. (TSX:NUMI)(OTCPK:LKYSF)(“Numinus” or the “Company”), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce the voting results from its Annual ... [Read]
Numinus to Participate in AAAS 2022 Annual Meeting on February 17-20, 2022
Dr. Devon Christie, Dr. Robin Carhart-Harris, Dr. Frederick Barrett and Tura Patterson will discuss “Psychedelic Research: Moving Beyond the Social and Political Stigma” VANCOUVER, BC, Feb. 10, 2022 – Numinus Wellness Inc. (TSX:NUMI)(OTCPK:LKYSF)(“Numinus” or the ... [Read]
Numinus Appoints New Bioscience Advisors to Advance IP Development
Advisors lead their fields in patent law, nutraceuticals & ethnobotany VANCOUVER, BC, Feb. 1, 2022 – Numinus’s Wellness Inc. (TSX:NUMI)(OTCPK:LKYSF)(“Numinus” or the “Company”), a mental healthcare company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is ... [Read]
Numinus Wellness Inc. Reports Q1 2022 Results
Ended the quarter with a strong cash position of $53.9 million Revenues grew 245% year-over-year to $0.8 million for the quarter Generated gross profit of $50,965 during the quarter, representing a 6.5% gross margin Well-positioned to offer psychedelic-assisted psychotherapy ... [Read]
Numinus Announces Key Milestones in MAPS-Sponsored MDMA-Assisted Therapy for PTSD Clinical Trial
Numinus has received approvals from Health Canada and the Institutional Ethics Review Board VANCOUVER, BC, Jan. 19, 2022 – Numinus Wellness Inc. (TSXV:NUMI) (“Numinus” or the “Company”), a leader in psychedelics-focused mental healthcare, is pleased ... [Read]
Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary Psilocybin Product
The trial evaluates Numinus’ first trademarked product and patent-pending production process VANCOUVER, BC, Jan. 14, 2022 – Numinus Wellness Inc. (TSXV:NUMI)(“Numinus“), a leader in psychedelics-focused mental healthcare, is pleased to announce that it has formally ... [Read]